Highlights
- •SIL6R and sgp130 had opposite associations with the MI risk.
- •Sgp130 reduces MI risk in individuals with high sIL6R.
- •These biomarkers may represent novel targets for prevention and treatment of MI.
Abstract
Objective
To investigate the association between circulating levels of the soluble interleukin
6 receptor (sIL6R) and the soluble gp130 (sgp130) with myocardial infarction (MI)
and to explore the potential interaction between sIL6R and sgp130 in this association.
Methods
Study population is the Stockholm Heart Epidemiology Program (SHEEP), a population-based
case–control study. SIL6R (ng/mL) and sgp130 (ng/mL) levels were measured in serum
samples from 682 and 664 MI cases and 1103 and 1062 controls, respectively. Odds ratios
(with 95% CIs) for MI were calculated using unconditional logistic regression. We
adjusted for age, sex, hospital catchment area (crude) and for hypertension, diabetes,
hypercholesterolemia, body mass index and smoking (adjusted model). Synergy index
(S) and attributable proportion (AP) were estimated as measures of biological interaction.
Results
Elevated concentrations of sIL6R (>75th percentile value) were associated with an
increased occurrence of MI (compared to ≤75th percentile), with an adjusted OR of
1.4 (95% CI, 1.1–1.8). Very high (>90th percentile value) levels of sgp130 were associated
with a reduced occurrence of MI [OR 0.7 (95% CI, 0.5–0.9)] (adjusted). There was an
indication of a possible interaction between high sIL6R and low sgp130 (adjusted S
score 1.7, 95% CI = 0.5–6.1; AP 0.19, 95% CI = −0.2–0.5), suggesting that low sgp130
levels may synergize with high sIL6R levels to increase risk of MI.
Conclusions
sIL6R and sgp130 had opposing associations with MI. Indeed, circulating sgp130 levels
may modify the association of elevated sIL6R levels with MI.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The soluble interleukin 6 receptor: mechanisms of production and implications in disease.FASEB J. 2001 Jan; 15: 43-58
- Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy.Cardiol. Rev. 2014 May-Jun; 22: 147-151
- The interleukin-6 pathway and atherosclerosis.Lancet. 2012 Mar 31; 379: 1176-1178
- IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.Int. J. Biol. Sci. 2012; 8: 1237-1247
- Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice.Arterioscler. Thromb. Vasc. Biol. 2012 Feb; 32: 281-290
- Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction.Atherosclerosis. 2003 Dec; 171: 359-367
- Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.Circulation. 2000 Apr 18; 101: 1767-1772
- Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction.Cardiology. 2000; 93: 191-196
- IL-6 and its receptors in coronary artery disease and acute myocardial infarction.Cytokine. 2013 Jun; 62: 395-400
- Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Circ. Heart Fail. 2013 Jan; 6: 91-98
- Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levels.Thromb. Haemost. 2009 May; 101: 943-953
- Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group.J. Intern. Med. 1999 Aug; 246: 161-174
- (visfatin) and AKT1 genetic variants associate with myocardial infarction.Clin. Chim. Acta. 2012 Apr 11; 413: 727-732
- The risk of myocardial infarction is enhanced by a synergistic interaction between serum insulin and smoking.Eur. J. Endocrinol. 2002 Nov; 147: 641-647
- Epidemiology: An Introduction.second ed. 2012
- Estimating measures of interaction on an additive scale for preventive exposures.Eur. J. Epidemiol. 2011 Jun; 26: 433-438
- Calculating measures of biological interaction.Eur. J. Epidemiol. 2005; 20: 575-579
- Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.Immunity. 1997 Mar; 6: 315-325
- Regulatory T-cell immunity and its relevance to atherosclerosis.J. Intern. Med. 2008 May; 263: 489-499
- A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis.Atherosclerosis. 2011 Dec; 219: 734-736
- IL-6 signalling in patients with acute ST-elevation myocardial infarction.Res. Immunol. 2014; 4: 8-13
- IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL.Res. Immunol. 2012; 2: 13-18
- Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men.Atherosclerosis. 2014 Oct; 236: 394-399
- Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.J. Leukoc. Biol. 2006 Aug; 80: 227-236
- Therapeutic blockade of interleukin-6 in chronic inflammatory disease.Clin. Pharmacol. Ther. 2012 Apr; 91: 574-576
- The interleukin 6 pathway and atherosclerosis.Lancet. 2012 Jul 28; 380: 338
- How much is too much? Interleukin-6 and its signalling in atherosclerosis.Thromb. Haemost. 2009 Aug; 102: 215-222
- Role of smooth muscle cells in the initiation and early progression of atherosclerosis.Arterioscler. Thromb. Vasc. Biol. 2008 May; 28: 812-819
- Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.Semin. Immunol. 2013 Dec 7;
- Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke.Ann. Rheum. Dis. 2011 Mar; 70: 508-511
- The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women.J. Intern. Med. 2002 Oct; 252: 332-341
- Chromosome 1p13 genetic variants antagonize the risk of myocardial infarction associated with high ApoB serum levels.BMC Cardiovasc. Disord. 2012; 12: 90
- The interaction between coagulation factor 2 receptor and interleukin 6 haplotypes increases the risk of myocardial infarction in men.PLoS One. 2010; 5: e11300
- Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis.Nat. Genet. 2009 Dec; 41: 1319-1324
- Recommendations for presenting analyses of effect modification and interaction.Int. J. Epidemiol. 2012 Apr; 41: 514-520
- Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance.Atherosclerosis. 2010 Nov; 213: 319-324
- Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.N. Engl. J. Med. 1985 Dec 19; 313: 1557-1563
- Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction.Atherosclerosis. 1986 Feb; 59: 223-235
- Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction.Am. Heart J. 1999 Nov; 138: 908-915
- Effects of low-dose aspirin on acute inflammatory responses in humans.J. Immunol. 2009 Aug 1; 183: 2089-2096
Article info
Publication history
Published online: April 13, 2015
Accepted:
April 13,
2015
Received in revised form:
April 11,
2015
Received:
January 14,
2015
Identification
Copyright
© 2015 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
